News

Kymab receives $40 million investment for clinical development of antibody therapeutics.

Merck KGaA fill-finish expansion in Italy will be completed in 2017.

SAFC offers commercial and pilot-scale continuous-flow capacity.

DA approves Entyvio, an injection to treat adult patients with moderate to severe ulcerative colitis and Crohn's disease.

FDA issues complete response letter for Novartis' RLX030 for acute heart failure.

Meissner moves into its new headquarters in Camarillo, California.

SGS makes two senior appointments at its new GMP/GLP laboratory in Carson, California.

AstraZeneca rejects Pfizer's final offer of $118 billion for a proposed merger of the two companies.

Advanced Scientifics and Chemic Laboratories enter a three-year joint cooperation agreement to collaborate on product development projects.

AstraZeneca will collaborate with the Medical Research Council Laboratory of Molecular Biology to fund a range of pre-clinical research projects.

EMA opens registration for it's sixth annual workshop on pediatric drug research and development.

Hillary Clinton will deliver a keynote address at the 2014 BIO International Convention in San Diego.

FDA and EMA release a draft joint proposal on the development of new drugs to treat Gaucher disease in children.

FDA clarifies stability data recommendations for abbreviated new drug applications.

Draft guidance addresses the use of clinical pharmacology studies to determine biosimilarity of biologics.

Eurofins Scientific will acquire ViraCor-IBT Laboratories for $255 million.

KBI Biopharma acquires Merck's microbial process development and manufacturing operations in Colorado.

Shire expands rare disease portfolio with acquisition of Lumena Pharmaceuticals.

Cumberland Pharmaceuticals and Gloria Pharmaceuticals invest $1 million each in Cumberland Emerging Technologies.

Boehringer Ingelheim and Connexios Life Sciences announce global research collaboration agreement for AMPK agonists.

Scientists at the National Cancer Institute found a new cancer immunotherapy method that could be effective against a wide range of cancers.

The Pediatric Clinical Research Group initiative expands to include pediatric research sites.

A multi-institutional effort will fight pediatric leukemia and neuroblastoma.

FDA releases draft guidance on the development of drugs to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia.

The Fogarty International Center, a component of the US NIH, calls for a focus on noncommunicable diseases and implementing science in low-resource settings.

WHO report provides a comprehensive picture of antibiotic resistance and suggests strategies to fight resistance.

AstraZeneca rejects $106 billion offer; Pfizer states its case for the merger with British government.

Gallus BioPharmaceuticals enters a cell line optimization and manufacturing agreement with Omni Bio Pharmaceutical.